In November 2020 OssDsign completed the acquisition of the privately held Scottish bone graft specialist company Sirakoss Ltd, expanding into the spinal bone graft market. The acquisition broadens OssDsign’s product portfolio with a 510(k) cleared next-generation nanosynthetic bone graft substitute designed for treating skeletal defects. Sirakoss has been preparing for a commercial launch since the product received FDA clearance in June 2020, and OssDsign intends to start commercial activities in the US market for spinal fusion during the second half of 2021.